HORMONE REPLACEMENT AND RISK OF UTERINE FIBROID GROWTH

描述：（改编自申请人的摘要）。 子宫疾病 子宫肌瘤是一个常见且重要的公共卫生问题，影响女性 所有年龄、种族背景和社会经济水平的人。 当女性与 肌瘤到达围绝经期或绝经后时期，它们面临着 令人不安的治疗困境。 如果她们想保留子宫， 服用激素替代疗法（HRT）会带来导致肌瘤生长的未知风险。 另一方面 另一方面，使用 HRT 的好处是巨大的，特别是对于女性来说 心血管疾病或骨质疏松症的风险。 已经很少了，如果 任何一项研究，旨在检查激素替代疗法（HRT）的使用对肌瘤增殖的影响 和子宫肌瘤患者的生长。 提议的随机化， 对照、双盲临床试验将调查其程度 通常采用低剂量、连续雌激素-孕激素 HRT 疗法刺激黑人和白人肌瘤的生长和增殖 绝经后肌瘤患者。 将进行超声波评估 针对 300 名绝经后肌瘤患者在基线、6、12 和 24 个月时的情况， 这将允许检查肌瘤生长的程度 如果发生的话，增长是持续还是停滞不前。 程度到 该 HRT 方案会影响更年期相关症状、子宫肌瘤相关症状 还将检查症状和生活质量。 风险收益分析 将在考虑子宫和非子宫风险的情况下进行 和好处，基于本研究的结果和其他研究的评论 研究。 这项研究的结果将具有重要价值 越来越多的肌瘤患者进入更年期并进入 治疗这些患者的临床医生。

DESCRIPTION: (Adapted from Applicant's Abstract). The disease of uterine fibroids is a common and significant public health problem, affecting women of all ages, racial backgrounds and socioeconomic levels. When women with fibroids reach the perimenopausal or postmenopausal periods, they face a troubling treatment dilemma. If they wish to preserve their uterus, they take an unknown risk of causing fibroid growth by taking HRT. On the other hand, the benefits of using HRT are substantial, particularly for women at risk for cardiovascular disease or osteoporosis. There are been little, if any, research done to examine the effect of HRT use on fibroid proliferation and growth among uterine fibroid patients. The proposed randomized, controlled, double-blinded clinical trial will investigate the extent to which a commonly prescribed low dose, continuous estrogen-progestin HRT regimen stimulates fibroid growth and proliferation among black and white postmenopausal fibroid patients. Ultrasound assessments will be conducted for 300 postmenopausal fibroid patients at baseline, 6, 12 and 24 months, which will allow an examination of the extent to which fibroid growth occurs, and if so, whether growth continues or plateaus. The extent to which this HRT regimen affects menopause-related symptoms, fibroid-related symptoms and quality of life will also be examined. A risk-benefit analysis will be conducted, taking into account both uterine and non-uterine risks and benefits, based on the results of this study and reviews of other studies. The results of this study will be of significant value to a growing body of fibroid patients reaching the menopause and to the clinicians who treat these patients.